Amobarbital is a federally controlled substance in the United States. It is listed as a Schedule II controlled substance under the Controlled Substances Act, placing it in the same regulatory tier as oxycodone and fentanyl. This classification reflects the government’s determination that amobarbital carries a high potential for abuse and can lead to severe physical dependence.
How Amobarbital Is Scheduled
The Drug Enforcement Administration (DEA) lists amobarbital under Schedule II, which is reserved for drugs with accepted medical uses but a high risk of abuse. In its pure form, or in any preparation where it is the sole active ingredient, amobarbital falls squarely into this category.
There is one important exception. When amobarbital is combined with one or more other active medicinal ingredients that are not themselves controlled substances, the resulting product drops to Schedule III. This lower schedule reflects the idea that combination products are somewhat harder to abuse for the barbiturate alone. The same dual-scheduling rule applies to two other barbiturates: pentobarbital and secobarbital. So when you see amobarbital referenced as both Schedule II and Schedule III, the difference comes down to whether it’s on its own or mixed into a combination formula.
International Controls
Amobarbital is also regulated internationally. Under the United Nations Convention on Psychotropic Substances of 1971, it is placed in Schedule III, which requires signatory countries to implement prescription controls, limit access, and monitor trade. Most countries with modern pharmaceutical regulations treat amobarbital as a restricted or controlled drug in some form.
Why It’s Classified So Strictly
Amobarbital is an intermediate-acting barbiturate, a class of drugs that slows brain activity by boosting the effect of a natural calming chemical called GABA. Barbiturates increase the flow of chloride ions into nerve cells, which dampens electrical signaling throughout the central nervous system. The result is sedation, drowsiness, and at higher doses, full anesthesia.
This powerful sedative effect is exactly what makes barbiturates dangerous. The body builds tolerance relatively quickly, meaning a person needs higher doses to achieve the same effect. Physical dependence follows, and stopping abruptly after prolonged use can trigger a withdrawal syndrome that is genuinely life-threatening. Withdrawal symptoms range from anxiety, tremors, insomnia, and nausea to far more serious complications like delirium, seizures, and cardiovascular collapse. Amobarbital is specifically named among the barbiturates most associated with severe withdrawal, alongside pentobarbital, secobarbital, and butalbital.
What Amobarbital Was Used For
Amobarbital has a labeled indication for insomnia, though the American Academy of Sleep Medicine does not endorse barbiturates for that purpose. In clinical settings, it was more commonly used for sedation before medical procedures, administered by injection at doses of 30 to 50 mg given two to three times daily as needed.
The drug also has a colorful history beyond routine sedation. Starting in the late 1920s, physicians discovered that patients given sub-anesthetic doses of amobarbital became unusually talkative and seemingly uninhibited in the minutes before falling asleep. Psychiatrists used this effect in “sodium amytal interviews” to help patients with trauma or psychosis discuss personal problems they otherwise could not articulate. The technique earned amobarbital the nickname “truth serum,” a term that first appeared in a 1922 newspaper after a Texas obstetrician interviewed two prisoners under the drug’s influence, both of whom were later found not guilty in court.
Military and intelligence agencies took notice. During World War II, researchers explored amobarbital as a treatment for combat-related psychological injuries and as a potential interrogation tool. During the Korean War, U.S. prisoners of war were reportedly subjected to amobarbital-assisted “brainwashing.” However, controlled studies ultimately showed the drug did not reliably compel truthfulness. Participants instructed to memorize false statements were able to maintain those falsehoods even while under amobarbital’s influence.
Current Availability
For practical purposes, amobarbital is no longer commercially available in the United States. Bausch Health, the sole manufacturer of Amytal Sodium (the brand-name injectable form), discontinued the product in August 2024. There are currently no other suppliers or alternative presentations on the market. This means that while amobarbital remains a legally recognized controlled substance with an active DEA schedule listing, obtaining it through normal pharmaceutical channels is not possible at this time.
The discontinuation reflects a broader trend. Barbiturates have been largely replaced by safer alternatives for both insomnia and procedural sedation. Newer sleep medications and sedatives carry a lower risk of fatal overdose and less severe withdrawal profiles, which has steadily pushed barbiturates to the margins of modern prescribing.
Legal Consequences of Possession
Because amobarbital is a Schedule II substance in its pure form, possessing it without a valid prescription is a federal crime. Manufacturing, distributing, or dispensing it outside legal channels carries the same penalties as other Schedule II drugs, which can include significant prison time and fines depending on the quantity involved and whether the offense is a first or repeat violation. Even the Schedule III combination products carry criminal penalties for unauthorized possession or distribution, though the maximum sentences are somewhat lower than for Schedule II offenses.